Evidence map›Paper›PMID 41440020›Full record

ArticleCells2025

Current Status and Future Challenges of Liquid Biopsy.

Shuta Ohara, Kenichi Suda

Abstract readEditorial
In one paragraph

Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Shuta OharaDivision of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, 1-14-1 Mihara-dai, Minami-ku, Sakai 590-0197, Japan.ORCID 0000-0002-9159-8743
Kenichi SudaDivision of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, 1-14-1 Mihara-dai, Minami-ku, Sakai 590-0197, Japan.ORCID 0000-0002-0842-8832

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liquid biopsy has rapidly advanced as an innovative tool in precision oncology, allowing clinicians to capture the dynamic molecular and/or quantitative changes in tumors with minimal invasiveness [...].

Indexed as

NeoplasmsBiomarkers, TumorHumansLiquid BiopsyPrecision MedicineBiomarkers, Tumor

Identifiers

PMID41440020
PMCPMC12731910

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.